, Volume 57, Issue 1, pp 57–62 | Cite as

Blockade of photically induced epilepsy by ‘dopamine agonist’ ergot alkaloids

  • Gill Anlezark
  • Brian Meldrum


The effect of the intravenous administration of ergot alkaloids on epileptic responses to intermittent photic stimulation (IPS) has been studied in adolescent baboons, Papio papio, from Senegal. Ergocormine, 1–2 mg/kg, produced marked autonomic and behavioural effects, slowed the EEG, and abolished myoclonic responses to IPS for 30–90 min. Ergometrine, 1 mg/kg, activated the EEG and blocked the induction of myoclonic responses for 1–3 h. Bromocriptine, 0.5–4 mg/kg, did not consistently prevent myoclonic responses to IPS. After pretreatment with a subconvulsant dose of allylglycine (180–200 mg/kg), lysergic acid diethylamide, 0.1 mg/kg, retained the capacity to block myoclonic responses to IPS, and ergocornine 1 mg/kg reduced such responses. The convulsant effect of allylglycine was enhanced, however, so that prolonged seizure sequences began 19–96 min after ergocornine administration. The protective action of ergot alkaloids against epileptic responses induced by sensory stimulation is interpreted in terms of effects at several sites, including dopaminergic and serotoninergic synapses.

Key words

Ergot alkaloids Reflex epilepsy Photosensitive baboons Dopamine Allylglycine Ergocornine 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Aghajanian, G. K., Haigler, H. H., Bloom, F. E.: Lysergic acid diethylamide and serotonin: direct actions on serotonin-containing neurons in rat brain. Life Sci. 11, 615–622 (1972)Google Scholar
  2. Aghajanian, G. K.: LSD and C.N.S. transmission. Annu. Rev. Pharmacol. 12, 157–168 (1972)Google Scholar
  3. Anlezark, G. M., Pycock, C., Meldrum, B. S.: Ergot alkaloids as dopamine agonists; comparison in two rodent models. Eur. J. Pharmacol. 37, 295–302 (1976)Google Scholar
  4. Ashton, C., Anlezark, G., Meldrum, B. S.: Inhibition of reflex epilepsy by (±) N-n-propylnorapomorphine. Eur. J. Pharmacol. 39, 399–401 (1976)Google Scholar
  5. Burt, D. R., Creese, I., Snyder, S. H.: Binding interactions of lysergic acid diethylamide and related agents with dopamine receptors in the brain. Mol. Pharmacol. 12, 631–638 (1976)Google Scholar
  6. Cools, A. R., Struyker Boudier, H. A. J., Van Rossum, J. M.: Dopamine receptors: selective agonists and antagonists of functionally distinct types within the feline brain. Eur. J. Pharmacol. 37, 283–293 (1976)Google Scholar
  7. Corrodi H., Farnebo, L.-O., Fuxe, K., Hamberger, B.: Effect of ergot drugs on central 5-hydroxytryptamine neurons: evidence for 5-hydroxytryptamine receptor stimulation. Eur. J. Pharmacol. 30, 172–181 (1975)Google Scholar
  8. Corrodi, H., Fuxe, K., Hökfelt, T., Lidbrink, P., Ungerstedt, U.: Effect of ergot drugs on central catecholamine neurons. Evidence for a stimulation of central dopamine neurons. J. Pharm. Pharmacol. 25, 409–412 (1973)Google Scholar
  9. Curtis, D. R., Davis, R.: Pharmacological studies upon neurones of the lateral geniculate nucleus of the cat. Br. J. Pharmacol. 18, 217–246 (1962)Google Scholar
  10. Da Prada, M., Saner, A., Burkard, W. P., Bartholini, G., Pletscher, A.: Lysergic acid diethylamide: evidence for stimulation of cerebral dopamine receptors. Brain Res. 94, 67–73 (1975)Google Scholar
  11. Elkhawad, A. O., Munday, K. A., Poat, J. A., Woodruff, G. N.: The effect of dopamine receptor stimulants on locomotor activity and cyclic AMP levels in the rat striatum. Br. J. Pharmacol. 54, 107–144 (1975)Google Scholar
  12. Fuxe, K., Corrodi, H., Hökfelt, T., Lidbrink, P., Ungerstedt, H.: Ergocornine and 2-Br-α-ergocryptine. Evidence for prolonged dopamine receptor stimulation. Med. Biol. 52, 121–132 (1974)Google Scholar
  13. Horton, R. W., Meldrum, B. S.: Seizures induced by allylglycine, 3-mercaptopropionic acid and 4-deoxypyridoxine in mice and photosensitive baboons, and different modes of inhibition of cerebral glutamic acid decarboxylase. Br. J. Pharmacol. 49, 52–63 (1973)Google Scholar
  14. Horton, R. W., Pycock, C. J.: Circling behaviour in rodents following an imbalance of basal ganglia GABA concentrations. Pharmacol. Biochem. Behav. 6, 493–497 (1977)Google Scholar
  15. Johnson, A. M., Loew, D. M., Vigouret, J. M.: Stimulant properties of bromocryptine on central dopamine receptors in comparison to apomorphine, (+)-amphetamine and l-dopa. Br. J. Pharmacol. 56, 59–68 (1976)Google Scholar
  16. Johnson, A. M., Vigouret, J. M., Loew, D. M.: Central dopaminergic actions of ergotoxine alkaloids and some derivatives. Experientia 29, 763 (1973)Google Scholar
  17. Meldrum, B., Anlezark, G., Trimble M.: Drugs modifying dopaminergic activity and behaviour, the EEG and epilepsy in Papio papio. Eur. J. Pharmacol. 32, 205–213 (1975a)Google Scholar
  18. Meldrum, B. S., Horton, R. W., Toseland, P. A.: A primate model for testing anticonvulsant drugs. Arch. Neurol. (Chicago) 32, 289–294 (1975b)Google Scholar
  19. Meldrum, B. S., Naquet, R.: Effects of psilocybin, dimethyltryptamine, mescaline and various lysergic acid derivatives on the EEG and on photically induced epilepsy in the baboon (Papio papio). Electroencephalogr. Clin. Neurophysiol. 31, 563–572 (1971)Google Scholar
  20. Orlowski, M., Reingold, D. F., Stanley, M. E.: d- and l-stereoisomers of allylglycine: convulsive action and inhibition of brain l-glutamate decarboxylase. J. Neurochem. 28, 349–353 (1977)Google Scholar
  21. Pieri, L., Pieri, M., Saner, A., Da Prada, M., Haefely, W.: A comparison of drug-induced rotation in rats lesioned in the medial forebrain bundle with 5,6-dihydroxytryptamine or 6-hydroxydopamine. Arch. Int. Pharmacodyn. 217, 118–130 (1975)Google Scholar
  22. Pijnenburg, A. J., Woodruff, G. N., Van Rossum J. M.: Ergometrine induced locomotor activity following intracerebral injection into the nucleus accumbens. Brain Res. 59, 289–302 (1973)Google Scholar
  23. Scheel-Krüger, J., Cools, A. R., Honig, W.: Muscimol antagonizes the ergometrine-induced locomotor activity in nucleus accumbens: evidence for a GABA-dopaminergic interaction. Eur. J. Pharmacol. 42, 311–313 (1977)Google Scholar
  24. Snider, S. R., Hutt, C., Stein, B., Fahn, S.: Increase in brain serotonin produced by bromocriptine. Neurosci. Lett. 4, 237–242 (1975)Google Scholar
  25. Tarsy, D., Pycock, C., Meldrum, B., Marsden, C. D.: Rotational behaviour induced in rats by intranigral picrotoxin. Brain Res. 89, 160–165 (1975)Google Scholar
  26. Trabucchi, M., Spano, P. F., Tonon, G. C., Frattola, L.: Effects of bromocriptine on central dopaminergic receptors. Life Sci. 19, 225–232 (1976)Google Scholar
  27. Von Hungen, K., Roberts, S., Hill, D. F.: LSD as an agonist and antagonist at central dopamine receptors. Nature 252, 588–589 (1974)Google Scholar
  28. Vuillon-Cacciuttolo, G., Balzano, E.: Action de quatre derivés de l'ergot sur la photosensibilité et l'EEG du Papio papio. J. Pharmacol. (Paris) 3, 31–45 (1972)Google Scholar
  29. Vuillon-Cacciuttolo, G., Meldrum, B. S., Balzamo, E.: Electroretinogram and afferent visual transmission in the epileptic baboon, Papio papio: effects of drugs influencing monoaminergic systems. Epilepsia 14, 213–221 (1973)Google Scholar
  30. Walter, S., Balzano, E. Vuillon-Cacciuttolo, G., Naquet, R.: Effects comportementaux et électrographiques du diethylamide de l'acide d-lysergique (LSD 25) sur le Papio papio photo-sensible. Electroencephalogr. Clin. Neurophysiol. 30, 294–305 (1971)Google Scholar
  31. Woodruff, G. N., Elkhawad, A. O., Crossman, A. R.: Further evidence for the stimulation of rat brain dopamine receptors by ergometrine. J. Pharm. Pharmacol. 26, 455–456 (1974)Google Scholar

Copyright information

© Springer-Verlag 1978

Authors and Affiliations

  • Gill Anlezark
    • 1
  • Brian Meldrum
    • 1
  1. 1.Department of NeurologyInstitute of PsychiatryLondonUK

Personalised recommendations